Eagle Health Investments LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 6, 2026), Eagle Health Investments LP reported 30 stock positions worth $455.1 million. Its top holding was Argenx SE - ADR (ARGX) at 11.6% of the portfolio, followed by Icon (ICLR, 9.9%) and Natera (NTRA, 9.2%). Compared with Q3 2025, it opened 11 new positions, sold out of 4, added to 3 and reduced 5. The biggest buy was a new position in Terns Pharmaceuticals (TERN) and the biggest sale an exit from Ultragenyx Pharmaceutical (RARE).
- Most Recent 13F
- Q2 2026
- Location
- Greenwich, CT
- CIK
- 0001842545
- Portfolio Value
- $455.1M (Q4 2025)
- SEC Filing
- 0001172661-26-000509 ↗ filed Feb 6, 2026
Holdings Value
Holdings 30 stocks · $455.1M
| ARGX Argenx SE - ADR | 11.59% | 62,730 | $52.8M | Reduce -19.0% |
| ICLR Icon PLC | 9.89% | 247,090 | $45.0M | Add +35.3% |
| NTRA Natera Inc. | 9.23% | 183,264 | $42.0M | Reduce -10.0% |
| INSM Insmed Inc. | 8.07% | 210,900 | $36.7M | Reduce -22.4% |
| ILMN Illumina Inc. | 6.66% | 231,161 | $30.3M | Reduce -28.3% |
| GH Guardant Health Inc. | 6.38% | 284,100 | $29.0M | No change |
| NBIX Neurocrine Biosciences Inc. | 5.07% | 162,800 | $23.1M | No change |
| BMRN Biomarin Pharmaceutical Inc. | 4.79% | 366,812 | $21.8M | No change |
| FTRE Fortrea Holdings Inc. | 4.62% | 1,218,560 | $21.0M | Add +23.2% |
| BBIO Bridgebio Pharma Inc. | 4.36% | 259,300 | $19.8M | No change |
| SRRK Scholar Rock Holding Corp. | 3.52% | 363,300 | $16.0M | No change |
| EXAS Exact Sciences Corp. | 3.30% | 147,750 | $15.0M | Reduce -45.5% |
| TERN Terns Pharmaceuticals Inc. | 2.44% | 275,090 | $11.1M | New |
| KYMR Kymera Therapeutics Inc. | 2.33% | 136,300 | $10.6M | New |
| CMPS Compass Pathways PLC | 2.30% | 1,519,388 | $10.5M | Add +62.4% |
| PRCT Procept Biorobotics Corp. | 2.13% | 308,434 | $9.7M | No change |
| RVMD Revolution Medicines Inc. | 2.03% | 115,900 | $9.2M | New |
| LEGN Legend Biotech Corp.-ADR | 1.95% | 408,652 | $8.9M | New |
| ATAIBECKLEY INC | 1.51% | 1,678,400 | $6.9M | New |
| SLNO Soleno Therapeutics Inc. | 1.37% | 135,100 | $6.3M | New |
| PTGX Protagonist Therapeutics Inc. | 1.10% | 57,300 | $5.0M | New |
| QURE Uniqure NV | 1.08% | 205,247 | $4.9M | New |
| PRAX Praxis Precision Medicines I | 0.97% | 14,951 | $4.4M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 0.57% | 103,100 | $2.6M | No change |
| ISRG Intuitive Surgical Inc. | 0.55% | 4,390 | $2.5M | No change |
| MLTX Moonlake Immunotherapeutics | 0.54% | 187,600 | $2.5M | New |
| ALKS Alkermes PLC | 0.50% | 81,800 | $2.3M | No change |
| IRON Disc Medicine Inc. | 0.47% | 27,100 | $2.2M | New |
| IMCR Immunocore Holdings PLC-ADR | 0.35% | 46,300 | $1.6M | No change |
| VIR Vir Biotechnology Inc. | 0.32% | 240,500 | $1.5M | No change |
Portfolio Sells Q3 2025 → Q4 2025
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −5.50 |
| ARGX Argenx SE - ADR | Reduce -19.0% | 11.59% | −3.40 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −2.84 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −2.82 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −2.59 |
| INSM Insmed Inc. | Reduce -22.4% | 8.07% | −2.20 |
| ILMN Illumina Inc. | Reduce -28.3% | 6.66% | −1.37 |
| EXAS Exact Sciences Corp. | Reduce -45.5% | 3.30% | −0.59 |
| NTRA Natera Inc. | Reduce -10.0% | 9.23% | +0.62 |
Portfolio Buys Q3 2025 → Q4 2025
| TERN Terns Pharmaceuticals Inc. | New | 2.44% | +2.44 |
| FTRE Fortrea Holdings Inc. | Add +23.2% | 4.62% | +2.43 |
| KYMR Kymera Therapeutics Inc. | New | 2.33% | +2.33 |
| RVMD Revolution Medicines Inc. | New | 2.03% | +2.03 |
| LEGN Legend Biotech Corp.-ADR | New | 1.95% | +1.95 |
| ATAIBECKLEY INC | New | 1.51% | +1.51 |
| ICLR Icon PLC | Add +35.3% | 9.89% | +1.51 |
| SLNO Soleno Therapeutics Inc. | New | 1.37% | +1.37 |
| PTGX Protagonist Therapeutics Inc. | New | 1.10% | +1.10 |
| QURE Uniqure NV | New | 1.08% | +1.08 |
| PRAX Praxis Precision Medicines I | New | 0.97% | +0.97 |
| CMPS Compass Pathways PLC | Add +62.4% | 2.30% | +0.90 |
| MLTX Moonlake Immunotherapeutics | New | 0.54% | +0.54 |
| IRON Disc Medicine Inc. | New | 0.47% | +0.47 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 27 | $603.3M | ARGX, ICLR, GH, INSM, BMRN |
| Q1 2026 | 26 | $476.3M | ARGX, ICLR, INSM, GH, BMRN |
| Q4 2025 | 30 | $455.1M | ARGX, ICLR, NTRA, INSM, ILMN |
| Q3 2025 | 23 | $380.9M | ARGX, INSM, NTRA, ICLR, ILMN |
| Q2 2025 | 21 | $405.2M | INSM, ARGX, NTRA, ILMN, ICLR |
| Q1 2025 | 20 | $385.1M | ARGX, NTRA, ICLR, INSM, ILMN |
| Q4 2024 | 18 | $407.9M | NTRA, ARGX, ILMN, ICLR, INSM |
| Q3 2024 | 24 | $518.7M | NTRA, ILMN, ARGX, ICLR, INSM |
| Q2 2024 | 25 | $559.6M | UTHR, NTRA, ICLR, UNH, ARGX |
| Q1 2024 | 26 | $524.8M | NTRA, ICLR, ILMN, UTHR, DXCM |